Analyzing the Metrics of Stocks Advertised on CNBC
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Commentary & Analysis
Financial Summary
| Share Statistics | CANF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.7 | $292.6 | 5% |
|
| Shares Out (Mil) | 2.2 | 54.4 | 8% |
|
| Institutional Ownership | 99.9% | 93.2% | 96% |
|
| Float (Mil) | 4.3 | 40.2 | 11% |
|
| Beta | -0.10 | 0.94 | 4% |
|
| Avg Daily Volume (000s) | 34 | 544 | 24% |
|
| Price Change (52-week) |
(74.7%) | 59.7% | 8% |
|
| Growth | CANF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (12.9%) | 13.6% | 4% |
|
| Net Income (5yr) | 7.4% | (10.1%) | 51% |
|
| EPS (5yr) | 45.7% | 16.0% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (60.8%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CANF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 1% |
|
| Net Income (TTM) (Mil) | ($10) | ($43) | 29% |
|
| EPS (TTM) | ($5.970) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $164 | 3% |
|
| Valuation | CANF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.56 | 2.83 | 40% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CANF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (105.5%) | (47.5%) | 5% |
|
| ROE | (178.2%) | (55.0%) | 5% |
|
| Liabilities to Assets | 41.2% | 29.6% | 32% |
|
| F-Score | 2 | 3 | 7% |
|
Can-Fite BioPharma Ltd. did not pass any screens on 8/21/2026.
